The research has been led by Dr. Sohini Sengupta and her team of experts after analyzing nearly 2,000 samples
India, September 20th, 2023: Redcliffe Labs, one of India’s fastest-growing omnichannel diagnostics service providers, announces groundbreaking achievement in women’s health research led by Dr. Sohini Sengupta, the Medical Laboratory Director. It is the first-ever study on Indian women for establishing age-specific reference intervals for Anti-Mullerian Hormone (AMH) and defining an AMH diagnostic cut-off for Polycystic Ovarian Syndrome (PCOS). The results will facilitate diagnosis accuracy and treatment of PCOS, a condition that affects approximately 11.34% of women in India.
Dr. Sohini Sengupta and her team of experts meticulously analyzed nearly 2,000 samples obtained from Indian women. The study suggests the optimal cut-off point of AMH for PCOS diagnosis in the Indian female population is 7.51ng/ml. With an impressive sensitivity of 99.4% and specificity of 95.5%, this diagnostic cut-off provides a highly accurate tool for healthcare professionals to swiftly and accurately identify PCOS in their patients. This innovative approach holds the potential to expedite PCOS diagnoses and facilitate timely interventions and treatments.
Healthcare providers in India have relied on AMH reference intervals and diagnostic thresholds derived from data collected from Caucasian women for years. Redcliffe Lab’s research is tailored specifically to the Indian female population and will provide healthcare professionals with a robust tool for better management and treatment of PCOS. This pioneering research has been published in the renowned International Journal of Reproduction, Contraception, Obstetrics, and Gynecology (IJRCOG).
Dr. Sohini Sengupta, Medical Laboratory Director at Redcliffe Labs, said, “Our findings represent a significant leap toward population-specific healthcare in India. Not only will they facilitate diagnosis and treatment of PCOS, but they also lay the groundwork for future research focused on localized medical data.”
About Redcliffe Labs
The brand ‘Redcliffe Labs’ was coined in the year 2021 when it ventured into routine diagnostics services with the foundation pillar to bring affordable & high-quality diagnostic services with ease of booking and home collection convenience, using the most advanced technology and processes, to people across the Indian subcontinent offering more than 3600+ tests for all age groups covering all major diseases with accurate results and fast turnaround time. Before that it operated under the brand name Redcliffe Lifesciences which was started in 2018 with a focus on specialized testing in reproductive care, oncology, rare diseases, and research. Redcliffe Labs services are currently available in 220+ cities across India through its wide network of more than 80 labs and 2000+ collection centres majorly targeting tier 2 and 3 masses. It conducts 7,000+ camps every month reaching the grassroots of the country and making quality diagnostics accessible to the masses.
